IP Library Granted Patent US 8,192,953
Granted Patent B2
US 8,192,953 · App. 12/405,003 · Granted Jun 5, 2012

Trimerising module

Assignees: Anaphore, Inc.; Hoffmann-La Roche, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,192,953
App. No.
12/405,003
Granted
Jun 5, 2012
Kind
B2
Abstract

The present invention relates to the design of trimeric polypeptides using polypeptide structural elements derived from the tetranectin protein family, and their use in rational de novo design and production of multi-functional molecules including the application of the multi-functional molecules in protein library technology, such as phage display technology, diagnostic and therapeutic systems, such as human gene therapy and imaging. The trimeric polypeptides being constructed as a monomer polypeptide construct comprising at least one tetranectin trimerising structural element (TTSE) which is covalently linked to at least one heterologous moiety, said TTSE being capable of forming a stable complex with two other TTSEs; or as an oligomer which is comprised of two monomer polypeptide constructs as mentioned above, and which comprises three TTSEs or a multiplum of three TTSEs, or which is comprised of three monomer polypeptide constructs.

Claims (36)

1. An isolated nucleic acid molecule encoding a monomer polypeptide comprising a trimerising structural element, wherein the polypeptide comprises:

(a) a tetranectin trimerising structural element (TTSE) sharing at least 68% amino acid sequence identity with the consensus sequence shown in SEQ ID NO:40, wherein the TTSE is not identical to the consensus sequence shown in SEQ ID NO:40, and (b) a heterologous amino acid sequence.

2. The isolated nucleic acid molecule of claim 1 , wherein the tetranectin trimerising structural element (TTSE) shares at least 75% amino acid sequence identity with the consensus sequence shown in SEQ ID NO: 40.

3. The isolated nucleic acid molecule of claim 1 , wherein the tetranectin trimerising structural element (TTSE) shares at least 81% amino acid sequence identity with the consensus sequence shown in SEQ ID NO: 40.

4. The isolated nucleic acid molecule of claim 1 , wherein the tetranectin trimerising structural element (TTSE) shares at least 87% amino acid sequence identity with the consensus sequence shown in SEQ ID NO: 40.

5. The isolated nucleic acid molecule of claim 1 , wherein the tetranectin trimerising structural element (TTSE) shares at least 92% amino acid sequence identity with the consensus sequence shown in SEQ ID NO: 40.

6. The isolated nucleic acid molecule of claim 1 , wherein the heterologous amino acid sequence comprises:

(a) a ligand binding structure;

(b) a detectable moiety;

(c) an in situ activatable substance;

(d) an enzyme; or

(e) a cytokine.

7. The isolated nucleic acid molecule of claim 1 , wherein the heterologous moiety does not exclusively facilitate expression and/or purification of the encoded monomer polypeptide.

8. An isolated nucleic acid molecule encoding a monomer polypeptide comprising a trimerising structural element, wherein the polypeptide comprises:

(a) a tetranectin trimerising structural element (TTSE) that comprises the sequence shown in SEQ ID NO:40, and

(b) a heterologous amino acid sequence, wherein the heterologous amino acid sequence does not exclusively facilitate expression and/or purification of the monomer polypeptide.

9. The isolated nucleic acid molecule of claim 8 , wherein the heterologous amino acid sequence comprises:

(a) a ligand binding structure;

(b) an in situ activatable substance;

(c) an enzyme; or

(d) a cytokine.

10. A recombinant host cell comprising the nucleic acid molecule of either claim 1 or 8 .

11. The recombinant host cell of claim 10 , wherein the recombinant host cell is a eukaryotic cell.

12. The recombinant host cell of claim 10 , wherein the recombinant host cell is a prokaryotic cell.

13. A vector comprising the nucleic acid molecule of either claim 1 or 8 .

14. A recombinant host cell comprising the vector of claim 13 .

15. The recombinant host cell of claim 14 , wherein the recombinant host cell is a eukaryotic cell.

16. The recombinant host cell of claim 14 , wherein the recombinant host cell is a prokaryotic cell.

17. A process of producing a monomer polypeptide encoded by the nucleic acid molecule of claim 1 , comprising culturing a recombinant host cell comprising the nucleic acid molecule of claim 1 under suitable conditions to express the polypeptide.

18. The process of claim 17 , further comprising recovering the monomer polypeptide from the culture.

19. A process of producing a monomer polypeptide encoded by the nucleic acid molecule of claim 1 , comprising culturing a recombinant host cell comprising a vector comprising the nucleic acid molecule of claim 1 under suitable conditions to express the polypeptide.

20. The process of claim 19 , further comprising recovering the monomer polypeptide from the culture.

21. A process of producing a monomer polypeptide encoded by the nucleic acid molecule of claim 8 , comprising culturing a recombinant host cell comprising the nucleic acid molecule of claim 8 under suitable conditions to express the polypeptide.

22. The process of claim 21 , further comprising recovering the monomer polypeptide from the culture.

23. A process of producing a monomer polypeptide encoded by the nucleic acid molecule of claim 8 , comprising culturing a recombinant host cell comprising a vector comprising the nucleic acid molecule of claim 8 under suitable conditions to express the polypeptide.

24. The process of claim 23 , further comprising recovering the monomer polypeptide from the culture.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 29, 2012
From: THOGERSEN, HANS CHRISTIAN; ETZERODT, MICHAEL; HOLTET, THOR LARS; GRAVERSEN, NIELS JONAS HEILSKOV; KASTRUP, JETTE SANDHOLM; NIELSEN, BETTINA BRYDE; LARSEN, INGRID KJOLLER
To: PROTEIN ENGINEERING TECHNOLOGY APS
Reel/Frame 027780/0472 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 29, 2012
From: ROCHE BIO DENMARK A/S
To: BOREAN PHARMA APS; HOFFMAN-LA ROCHE, INC.
Reel/Frame 027780/0669 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 29, 2012
From: BOREAN PHARMA APS
To: IMMUNONEWCO DK APS
Reel/Frame 027780/0764 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 29, 2012
From: IMMUNONEWCO DK APS
To: ANAPHORE, INC.
Reel/Frame 027780/0824 →
CHANGE OF NAME Recorded Feb 29, 2012
From: PROTEIN ENGINEERING TECHNOLOGY APS
To: BOREAN PHARMA APS
Reel/Frame 027781/0558 →
CHANGE OF NAME Recorded Feb 29, 2012
From: BOREAN PHARMA A/S
To: ROCHE BIO DENMARK A/S
Reel/Frame 027781/0589 →
Priority Claims (1)
DK 0685/97 · Jun 11, 1997 · national
Continuity (3)
Division 11452434 · Jun 14, 2006
Continuation 09445576
Related Publication 20100003719A1 · Jan 7, 2010